Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Roche
Pharma
Dupixent COPD delay possible, Eylea down 2%, Regeneron says
The FDA has requested more efficacy data for Sanofi and Regeneron's Dupixent in COPD. Additionally, Eylea sales fell by 2% in the first quarter.
Kevin Dunleavy
May 2, 2024 12:00pm
Pharma's reputation falls as pandemic-era halo slips
Apr 29, 2024 2:00am
Roche's juggernaut Vabysmo routs analyst consensus
Apr 24, 2024 11:29am
Orphan drug market to reach $270B by 2028: Evaluate
Apr 24, 2024 12:01am
Roche's Alecensa snags FDA postsurgery nod in lung cancer
Apr 19, 2024 11:03am
Roche touts near-complete MS suppression for injectable Ocrevus
Apr 17, 2024 11:00am